# Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation
Canonical URL: https://biopharmsignal.com/news/ALHC/alignment-healthcare-strengthens-leadership-team-to-support-long-term-growth-and-shareholder-value-creation
Ticker: ALHC
Company: Alignment Healthcare
Source: Alignment Healthcare
Published: 2026-05-12 20:30 EST
Original Source URL: https://ir.alignmenthealth.com
## Summary

Founder and CEO John Kao Assumes Additional Role as Chairman of the Board ORANGE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced leadership updates that further strengthen the organization as the company continues to scale for long-term growth.

## Article Body
Founder and CEO John Kao Assumes Additional Role as Chairman of the Board ORANGE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced leadership updates that further strengthen the organization as the company continues to scale for long-term growth.
## Recent Company News
- 2026-06-03 20:01 EST — [Alignment Healthcare Named to the Fortune 1000 2026 List for Second Consecutive Year](https://biopharmsignal.com/news/ALHC/alignment-healthcare-named-to-the-fortune-1000-2026-list-for-second-consecutive-year) — Source: Alignment Healthcare
- 2026-06-02 12:00 EST — [Alignment Healthcare Shows How Earlier, Coordinated Care Leads to Better Health and Fewer Emergencies in 2025 Impact Report](https://biopharmsignal.com/news/ALHC/alignment-healthcare-shows-how-earlier-coordinated-care-leads-to-better-health-and-fewer-emergencies-in-2025-impact-report) — Source: Alignment Healthcare
- 2026-05-18 12:00 EST — [Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/ALHC/alignment-healthcare-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Alignment Healthcare
- 2026-05-14 20:01 EST — [Alignment Health Plan Recognized as One of Four Medicare Advantage Prescription Drug Plans in the U.S. for 2026 Excellence in Quality](https://biopharmsignal.com/news/ALHC/alignment-health-plan-recognized-as-one-of-four-medicare-advantage-prescription-drug-plans-in-the-u-s-for-2026-excellence-in-quality) — Source: Alignment Healthcare
- 2026-05-12 20:30 EST — [Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation](https://biopharmsignal.com/news/ALHC/alignment-healthcare-strengthens-leadership-team-to-support-long-term-growth-and-shareholder-value-creation) — Source: Alignment Healthcare
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)